PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors,
including glioma. This makes it a potentially imaging target for the detection and grading of
gliomas. This pilot study was designed to evaluate the diagnostic performance of
68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with MRI in the
same group of glioma patients.